Advertisement

Topics

ANTABIO Completes € 12.5M Series A financing

10:00 EDT 13 Jul 2018 | Bionity

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment funds Omnes, BNP Paribas Développement, and Sham Innovation Santé ...

Original Article: ANTABIO Completes € 12.5M Series A financing

NEXT ARTICLE

More From BioPortfolio on "ANTABIO Completes € 12.5M Series A financing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...